The World Health Organization (WHO) announced today it is recommending widespread use of GSK’s Mosquirix RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and other regions with moderate to high P. falciparum malaria transmission.
The WHO recommendation is based on results from an ongoing pilot program in Ghana, Kenya, and Malawi that has reached more than 800,000 children since 2019.
To date, more than 2.3 million doses of the vaccine have been administered in African countries.
Malaria Vaccine Green-Lit by the WHO
Breakthrough COVID-19 Risk Up for Patients With Substance Use Disorders
After controlling for lifetime comorbidities and adverse socioeconomic determinants of health, infection risk increased only for cannabis use disorder
Outpatient Anticoagulant Therapy May Cut COVID-19 Admission Risk
COVID-19 inpatients not on anticoagulants before or after hospitalization have increased risk for mortality
Depressive Symptoms Up in U.S. Adults During the Pandemic
Mental health gap seen with greater risk for depressive symptoms among those with lower income, more pandemic-related stressors
Health Care Workers Show Greatest COVID-19 Stress
Findings compared to other occupational categories, but across occupations, women had high levels of stress, with age acting as a protective factor
U.S. to Buy $1 Billion Worth of Rapid COVID-19 Tests
Many Americans have reported difficulty getting testing appointments or buying at-home tests
Nearly 200,000 COVID-19 Home Tests Recalled Over False Positives
Problem with the rapid antigen tests was caused by variations in the quality of one of the raw materials used in the products
BNT162b2 Protects Against COVID-19 Hospitalization for Up to Six Months
Effectiveness of full vaccination against SARS-CoV-2 infections caused by the delta variant or other variants wanes more quickly